Long-term efficacy and safety of upadacitinib in patients with polyarticular-course juvenile idio...
November 13, 2026
Share
Long-term efficacy and safety of upadacitinib in patients with polyarticular-course juvenile idiopathic arthritis: 48 week results from the SELECT-YOUTH open-label study.